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ABSTRACT
Loss of epidermal growth factor receptor (EGFR) activity in mice alters growth plate development, impairs endochondral ossification, and
retards growth. However, the detailed mechanism by which EGFR regulates endochondral bone formation is unknown. Here, we show
that administration of an EGFR-specific small-molecule inhibitor, gefitinib, into 1-month-old rats for 7 days produced profound defects in
long bone growth plate cartilage characterized by epiphyseal growth plate thickening and massive accumulation of hypertrophic
chondrocytes. Immunostaining demonstrated that growth plate chondrocytes express EGFR, but endothelial cells and osteoclasts show
little to no expression. Gefitinib did not alter chondrocyte proliferation or differentiation and vascular invasion into the hypertrophic
cartilage. However, osteoclast recruitment and differentiation at the chondro-osseous junction were attenuated owing to decreased
RANKL expression in the growth plate. Moreover, gefitinib treatment inhibited the expression of matrix metalloproteinases (MMP-9, -13,
and -14), increased the amount of collagen fibrils, and decreased degraded extracellular matrix products in the growth plate. In vitro, the
EGFR ligand transforming growth factor a (TGF-a) strongly stimulated RANKL and MMPs expression and suppressed osteoprotegerin
(OPG) expression in primary chondrocytes. In addition, a mouse model of cartilage-specific EGFR inactivation exhibited a similar
phenotype of hypertrophic cartilage enlargement. Together our data demonstrate that EGFR signaling supports osteoclastogenesis at
the chondro-osseous junction and promotes chondrogenic expression of MMPs in the growth plate. Therefore, we conclude that EGFR
signaling plays an essential role in the remodeling of growth plate cartilage extracellular matrix into bone during endochondral
ossification. ß 2011 American Society for Bone and Mineral Research.
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Introduction

T

he majority of the mammalian skeleton, except for most
of the craniofacial skeleton, forms through the process of
endochondral ossification, in which a cartilage template is
replaced by bone. In long bones, this process occurs at the
primary and secondary ossification centers separated by the
growth plate. The growth plate consists of a distinct polarized
layer of chondrocytes. To achieve longitudinal growth, growth
plate chondrocytes go through several stages, including
proliferation, differentiation, hypertrophy, mineralization, and
apoptosis. At the chondro-osseous junction (COJ), the invasion
of hypertrophic cartilage by blood vessels, osteoclasts, and
osteoblast precursor cells, together with terminally differentiated

hypertrophic chondrocytes, leads to degradation and remodeling of the hypertrophic cartilage extracellular matrix (ECM) into
trabecular bone.
Endochondral ossification is tightly controlled by circulating
systemic hormones and locally produced signaling factors.
These include Indian hedgehog (Ihh), parathyroid hormone
(PTH) and parathyroid hormone–related protein (PTHrP) and
their receptor PTH1R, fibroblast growth factor 18 (FGF-18)
and its receptor FGFR3, vascular endothelial growth factor
(VEGF), connective tissue growth factor (CTGF), bone
morphogenetic proteins (BMPs), and Wnt proteins. In addition,
the transcription factors Sox9 and Runx2/Cbfa1 play major
roles in growth plate chondrocyte proliferation and
differentiation.(1,2)
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The epidermal growth factor receptor (EGFR) belongs to a
tyrosine kinase receptor family that also contains ErbB2, ErbB3,
and ErbB4. Its ligands include EGF, amphiregulin, and transforming growth factor a (TGF-a), which only bind to EGFR, and
heparin-binding EGF (HB-EGF), betacellulin, and epiregulin,
which bind to both EGFR and ErbB4. Upon ligand binding,
EGFR either homodimerizes or heterodimerizes with other ErbBs.
The dimerized receptors then undergo auto- or transphosphorylation on tyrosine residues in the intracellular domain,
thus activating several important intracellular signal-transduction pathways, including Ras-Raf-MAP-kinase and PI-3-kinaseAkt. ErbB2 is the preferred partner for EGFR, and the signals
mediated by EGFR/ErbB2 are thought to account for most of
EGFR’s biologic activities. EGFR signaling modulates a variety of
cell functions, such as proliferation, survival, adhesion, migration,
and differentiation.(3)
Egfr null mice usually die at midgestation, birth, or within
20 postnatal days depending on genetic background owing to
severe developmental abnormalities in placental, neural, and
epithelial tissues.(4–6) A few surviving Egfr null pups displayed
craniofacial alterations and cleft palates.(7) They also had delayed
primary endochondral ossification, an enlarged hypertrophic
zone in the growth plate, and impaired trabecular bone
formation during embryonic development.(8) Similarly, mice
expressing humanized EGFR (by replacement of the endogenous
mouse Egfr gene with human EGFR cDNA) exhibited low EGFR
activity in the skeleton and had a greatly enlarged hypertrophic
chondrocyte zone in the growth plate.(9) Overexpression of
herstatin, a soluble ErbB2 receptor that acts in a dominantnegative fashion to inhibit EGFR signaling, under the limbspecific Prx1 promoter in mice resulted in shortened limbs and
an expanded hypertrophic zone.(10) In contrast, mice ubiquitously overexpressing the EGFR ligand betacellulin had a smaller
hypertrophic zone regardless of age and sex.(11) In another
transgenic mouse model where human EGF was ubiquitously
expressed under the b-actin promoter, the proximal tibial
growth plate retained columns of prehypertrophic chondrocytes
that was not seen in control animals at 6 months of age.(12) Taken
together, these data clearly indicate that EGFR signaling plays an
important role in long bone development and endochondral
ossification, but the underlying mechanism is largely unknown.
Gefitinib is a Food and Drug Administration–approved smallmolecule EGFR inhibitor that blocks EGFR activity by competing
with ATP binding to the receptor’s kinase pocket.(13) In this study,
we treated young growing rats with gefitinib to investigate the
effects of blocking EGFR activity on endochondral ossification.
Using histologic analyses, immunohistochemistry, quantitative
measurement of gene and protein expression, and primary
chondrocyte cultures, we demonstrate that EGFR signaling plays
an essential role in the remodeling of growth plate cartilage ECM
into bone during endochondral ossification.

Materials and Methods
Animals
One-month-old male Sprague-Dawley rats (Taconic, Hudson, NY,
USA) were administered either vehicle (0.5% methyl cellulose) or
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gefitinib (100 mg/kg/d; LC Laboratories, Woburn, MA, USA) daily
by oral gavage for 7 days. There was no significant body weight
loss after treatment. After euthanization, blood was collected by
cardiac puncture to measure serum calcium ion concentration
(Calcium Reagent Set; Pointe Scientific, Canton, MI, USA). Femurs
and tibias were harvested and processed for growth plate tissue,
histologic analysis, micro–computed tomography (mCT), and
immunohistochemisty.
Egfrf/f,(14) EgfrWa5/þ,(15) and Col2a1-Cre(16) mouse strains were
used as described previously. To generate Col2a1-Cre EgfrWa5/f
mice, we first bred Col2a1-Cre mice with EgfrWa5/þ mice to obtain
Col2a1-Cre EgfrWa5/þ mice, which were then crossed with Egfrf/f
mice to generate Col2a1-Cre EgfrWa5/f mice and their siblings,
Col2a1-Cre Egfrf/þ, EgfrWa5/f, and Egfrf/þ mice. Col2a1-Cre EgfrWa5/f
mice were identified by their wavy coat appearance and PCR
genotyping of the Cre gene using primers 50 -GAG TGA TGA GGT
TCG CAA GA-30 and 50 -CTA CAC CAG AGA CGG AAA TC-30 .
All animal work performed in this study was approved by the
Institutional Animal Care and Use Committee (IACUC) at the
University of Pennsylvania.

Histologic analyses, immunohistochemistry,
and in situ hybridization
To study growth plate morphology and calcification of rat bones,
tibias were dissected, fixed in 70% ethanol, processed for methyl
methacrylate (MMA) embedding, and cut into 5-mm longitudinal
sections using a Reichert-Jung Polycut-S motorized microtome.
Consecutive sections were processed for Goldner’s trichrome
and von Kossa staining. Proliferative and hypertrophic zones of
the growth plate were measured on Goldner’s trichrome–stained
sections under the microscope at 100 magnification and
calculated as an average of three measurements of the left,
middle, and right regions of the growth plate. All sections were
collected from the centers of tibias. The proliferative zone is
defined as the area that contains flattened cells in a longitudinal
and columnar arrangement. The hypertrophic zone is defined as
the area at which the cell size starts to increase to the area where
cartilage becomes bone.(17,18)
For histologic staining, tartrate-resistant acid phosphatase
(TRAP) staining, and immunohistochemistry of rat bones, femurs
or tibias were fixed in 10% neutral buffered formalin overnight,
washed under tap water, and then decalcified in 0.5 M EDTA (pH
7.4) for 3 weeks prior to processing and embedding in paraffin.
Then 6-mm-thick sections were cut for analysis. For safranin O
staining, sections were stained with hematoxylin, followed by
0.001% (wt/vol) fast green and 0.1% (wt/vol) safranin O. For
TRAP staining, sections were stained using a leukocyte acid
phosphatase kit (Sigma-Aldrich, St Louis, MO, USA). TRAPþ cells
at the COJ and in the primary spongiosa were counted under the
microscope at 100 magnification. For immunohistochemistry,
sections were deparaffinized and washed in PBS. After antigen
retrieval, endogenous peroxidase activity was quenched in
3% H2O2 for 15 minutes and washed in PBS. Sections then were
blocked in blocking serum at room temperature for 1 hour and
incubated with a primary antibody at 4 8C overnight. After
washing in PBS, sections were incubated with a biotinylated
secondary antibody and then with an avidin-biotinylated
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horseradish peroxidase complex (Vectastain ABC Kit, Vector
Laboratories, Burlingame, CA, USA) according to the manufacturer’s directions. Finally, peroxidase activity was revealed by
immersion in DAB (Dako, Glostrup, Denmark). The following
primary antibodies were used: rabbit anti-Ki67 antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-p57
antibody (Abcam, Cambridge, MA, USA), rabbit anti-EGFR
antibody (Abcam), rabbit anti-type II collagen antibody (Abcam),
and rabbit anti-Col2-3/4C (MMP-13-generated type 2 collagen
cleavage fragment) antibody (a gift from Dr John S Mort). For
bromodeoxyuridine (BrdU) staining, rats were injected intraperitoneally with BrdU at a dose of 100 mg/g of body weight 2 hours
before euthanization. The staining was carried out on paraffin
sections using a BrdU staining kit (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s directions.
In situ hybridization of paraffin sections processed from
rat tibias was performed as described previously.(19) Highly
conserved regions between mouse and rat cDNA (over 93%
homology) were used as templates to generate probes: a 515 bp
mouse collagen 10a1 (1302–1816, NM _009925) and a 734-bp
mouse Mmp13 (11–744, BC125320).
To study mouse growth plate morphology, tibias were
dissected from P5 pups of Col2a1-Cre EgfrWa5/f mice and their
siblings and processed for paraffin sections. Sections were
stained with hematoxylin and eosin (H&E) and measured for
lengths of proliferative and hypertrophic zones, as described
earlier.

mCT measurement
The femurs were subjected to ex vivo mCT analysis (Skyscan1172
High-Resolution mCT; Skyscan, Aartselaar, Belgium). To study the
trabecular architecture of the distal femoral metaphysis, primary
and secondary spongiosa areas, corresponding to 0.5 to 2.3 and
2.3 to 3.8 mm, respectively, below the lowest point of growth
plate, were scanned at 10-mm resolution and analyzed using 3D
analysis.

Growth plate tissue harvest, RNA and protein analyses
Rat tibias were dissected free of soft tissue, and their proximal
ends, containing the growth plate, were cut longitudinally into
approximately 0.5-mm-thick sections using a no. 22 surgical
scalpel blade. Only sections obtained from the centers of tibias
(approximately three to four sections per tibia) were used for the
microdissection. Under a dissection microscope, perichondrum
and epiphyseal bone were removed first from these sections, and
growth plate cartilage then was carefully dissected out from the
metaphyseal bone at the area just above the COJ (a fine red line)
with a no. 15 surgical scalpel blade. As shown in Supplemental
Fig. S1, cartilage harvested by this method contained only
chondrocytes and excluded cells located in the COJ and bone.
Growth plate tissues from the same bone were combined and
processed for the following analyses.
To obtain RNA, growth plate tissue was homogenized in Tri
Reagent (Sigma-Aldrich), followed by total RNA isolation and
purification. A Taqman Reverse Transcription Kit (Applied
BioSystems, Inc., Foster City, CA, USA) was used to reverse
transcribe mRNA into cDNA. Following this, quantitative real-
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time PCR (qRT-PCR) was performed using a Power SYBR Green
PCR Master Mix Kit (Applied BioSystems, Inc). The primer
sequences for the genes used in this study are listed in
Supplemental Table S1. Relative expression was calculated for
each gene by the 2DDCT method with b-actin for normalization.
To obtain protein, growth plate tissue was ground in a liquid
nitrogen–cooled pestle with a mortar and then dissolved in RIPA
buffer (Santa Cruz Biotechnology). Equal amounts of protein
lysates (30 mg/lane) were resolved by SDS-PAGE on 10%
polyacrylamide gels, transferred to polyvinylidene difluoride
membranes (Hybone-P; Amersham Biosciences, Pittsburgh, PA,
USA), and blotted with rabbit anti-MMP-9, anti-MMP-13, or antiMMP-14 antibodies (Abcam), anti-CGGVDIPEN (MMP-generated
aggrecan cleavage fragment) antibody (a gift from Dr John S
Mort), or mouse anti-b-actin antibody (Santa Cruz Biotechnology) at 4 8C overnight. After incubation with horseradish
peroxidase–conjugated secondary antibody, blots were developed by enhanced chemiluminescence (ECL; GE Healthcare,
Piscataway, NJ, USA) following the manufacturer’s protocol and
visualized by exposure to X-ray film (Eastman Kodak, Rochester,
NY, USA).
Alternatively, total protein lysates (15 mg) were mixed with
2  sample buffer (4% SDS, 25% glycerol, 0.01% bromophenol
blue, and 62.5 mM Tris, pH 6.8) and loaded without boiling onto a
10% acrylamide gel copolymerized with 1 mg/mL of gelatin
(Sigma-Aldrich). After running at 100 V for 1.5 hours at 4 8C under
nonreducing conditions, the gel was washed twice in 2.5% Triton
X-100 for 30 minutes to allow enzyme renaturation and then
incubated in development buffer (Bio-Rad, Hercules, CA, USA) at
37 8C for 5 hours. The gel was stained with 0.5% Coomassie blue
R-250 (Thermo Scientific, Waltham, MA, USA) for 1 hour and
destained in 40% methanol, 10% acetic acid solution until
evidence of proteolytic activity appeared as clear bands against
the blue background.

Primary chondrocytes
Primary epiphyseal chondrocytes were isolated from the distal
femoral and proximal and distal tibial condyles of 1- to 3-day-old
Sprague-Dawley rats. Briefly, epiphyseal condyles were dissected, cleaned of connective tissue, and digested in type 2
collagenase solution (2.2 mg/mL in PBS; Invitrogen) at 37 8C with
gentle agitation for 30 minutes. The condyles were collected and
further digested for 4 hours. The supernatant was filtered and
centrifuged to collect chondrocytes. Cells were plated at a
density of 4  104 /cm2 in 24-well plates in chondrogenic
medium (DMEM/F12 medium with 5% fetal bovine serum,
50 mg/mL of L-ascorbic acid, 1% glutamine, 100 mg/mL of
streptomycin, and 100 U/mL of penicillin). Two to three days
later, when cells reached 90% confluence, cultures were given
fresh medium. The following day, cells were treated with 50 ng/
mL of recombinant human TGF-a (Pepro-Tech, Rocky Hill, NJ,
USA), and RNA and protein were harvested at indicated times
for analysis.

Statistical analysis
All data were analyzed by independent Student’s t test assuming
equal variances in each group or two-way ANOVA with a
ZHANG ET AL.

Bonferroni post-test. Animal number per group varied from three
to six. For cell culture experiments, all results are derived from
experiments being repeated independently at least three times.
A value of p < 0.05 was considered significant. All data are
expressed as mean  SEM.

Results
Inhibition of EGFR activity altered growth
plate architecture
To study the role of EGFR in postnatal growth plate development,
we administered an EGFR-specific inhibitor, gefitinib, to 1month-old rats for 7 days. Gefitinib-treated rats developed
profound changes in the growth plate cartilage in both femurs
and tibias that were characterized by epiphyseal growth plate
thickening and accumulation of hypertrophic chondrocytes
(Fig. 1A, B). In these animals, we observed an overall 2.0-fold
increase in the tibial growth plate length. This is due mainly to a
striking increase in the length of the hypertrophic zone (2.3-fold).
There was no significant change in the length of the proliferative
zone (1.2-fold increase, p ¼ 0.07; Fig. 1C, D, G). The enlargement
of the hypertrophic zone is due mainly to an increase in
the number of chondrocytes but not an increase in cell size
because the cell number per length remains the same (Fig. 1H).
The expansion of the hypertrophic zone also was confirmed by
safranin O staining, which showed less staining intensity in the
hypertrophic zone than in the proliferative zone (Fig. 1E, F).
In addition, immunostaining for Ki67, a marker for replicating
cells, and p57, a marker for cell cycle exit, as well as in situ
hybridization for Col10a1, a hypertrophic zone marker, further
demonstrated that elongation of the growth plate in gefitinibtreated rats was due mainly to expansion of the hypertropic zone
(Supplemental Fig. S2). This change in the growth plate was
reversible because the length of the growth plate returned to
normal 1 week after withdrawal of the EGFR inhibitor (data not
shown). A similar phenotype also was noticed with rats treated
with another EGFR-specific inhibitor, erlotinib (data not shown),
confirming that this growth plate phenotype results from the
loss of EGFR activity. In addition, we observed a small but
significant decrease in the long bone length (for tibia, vehicle
22.3  0.2 mm versus gefitinib 20.5  0.3 mm, p ¼ 0.02; for femur,
vehicle 25.7  0.4 mm versus gefitinib 24.1  0.3 mm, p ¼ 0.03,
n ¼ 3 to 6/group) after 7 days of treatment.
The primary spongiosa of metaphyseal bone underneath the
growth plate is derived directly from the hypertrophic zone
through a bone-modeling process. In normal rats, bone spicules
in this area were extended from the chondrocyte columns and
parallel to each other. However, gefitinib-treated rats had shorter
bone spicules with irregular shapes (Fig. 2A, B). Interestingly,
we noticed that there were more cartilage remnants in the
bone spicules (light blue areas in Fig. 2A) in gefitinib-treated rats
than in vehicle-treated rats, implying that gefitinib delays the
conversion of cartilage matrix into bone matrix.
mCT imaging further confirmed this phenomenon and the
expansion of the growth plate (Fig. 2B). Quantitative analyses
showed that the bone volume in the primary spongiosa
was decreased significantly by 14% in gefitinib-treated rats
ROLE OF EGFR IN ENDOCHONDRAL OSSIFICATION

(Fig. 2C). This was due mainly to an elevation in trabecular
separation (22%) and a reduction in trabecular number (14%).
The trabecular thickness was not changed in this area. In
the secondary spongiosa, where bone remodeling occurs, we
observed a larger decrease in bone volume (36%) with similar
changes in trabecular separation (19% increase; not significant)
and trabecular number (36%; Fig. 2D). This result is consistent
with our recent finding that gefitinib treatment decreases bone
volume and inhibits bone formation in young mice.(20) Overall,
these data indicate that postnatal long bone growth is affected
by the loss of EGFR activity.

Gefitinib treatment delayed cartilage mineralization.
Next, we investigated whether cartilage mineralization was
altered in the growth plates of gefitinib-treated rats. In
agreement with numerous reports, von Kossa staining revealed
that about one-half to two-thirds of the hypertrophic zones in
the growth plates of normal rats were calcified (Supplemental
Fig. S3A, B). However, after gefitinib treatment, only the last two
to three rows of chondrocytes in the hypertrophic zones were
mineralized (Supplemental Fig. S3C, D). This enlargement of
growth plate and delayed mineralization are reminiscent of
osteomalacia, a disease caused by the depletion of calcium.
However, we did not observe any changes in the serum
calcium ion level (vehicle 12.2  0.7 mg/dL versus gefitinib
12.5  0.2 mm, p ¼ 0.87, n ¼ 6/group). Moreover, no expanded
osteoid was observed in the trabecular bone of gefitinib-treated
animals (Fig. 1A, B and Fig. 2A), suggesting that this phenomenon
is not a result of altered calcium homeostasis.

Growth plate chondrocytes express EGFR
We performed immunohistochemistry to identify the cells that
express EGFR protein in the growth plate. As shown in
Supplemental Fig. S4A, B, strong EGFR expression was detected
in all chondrocytes within the growth plate, suggesting that
growth plate chondrocytes are the primary target for gefitinib.
In addition, we observed very weak to no EGFR staining in the
endothelial cells (Supplemental Fig. S4C) and multinucleated
osteoclasts (Supplemental Fig. S4D) and strong staining in
osteoblasts (Supplemental Fig. S4C) in the primary spongiosa.
These data are in agreement with our previous report that
osteoblasts express EGFR but that osteoclast progenitors and
mature osteoclasts do not bind EGF ligand and do not possess
functional EGFR.(21)

Chondrocyte proliferation and differentiation are
unchanged in gefitinib-treated rats
The expansion of the growth plate in gefitinib-treated rats could
be the result of increased chondrocyte cell proliferation or
altered differentiation. The aforementioned data demonstrating
that gefitinib expands the hypertrophic zone but has no effect on
the length of the proliferative zone provided the first hint that
gefitinib does not change the proliferation and differentiation of
chondrocytes in vivo. To further test this, we labeled rats with
BrdU. Tibias harvested from gefitinib-treated rats contained
a similar percentage of BrdUþ cells in the proliferative zone
(vehicle 22.6%  1.7% versus gefitinib 22.4%  2.3%, n ¼ 3/
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Fig. 1. In vivo inhibition of EGFR activity expands the long bone growth
plates. One-month-old rats were treated with either vehicle (A, C, E) or
gefitinib (B, D, F) for 7 days, and their tibias were processed for MMA
sections (A–D) or paraffin sections (E, F) for histologic examination.
Staining of the bone with Goldner’s trichrome showed a striking enlargement of the growth plate, particularly the hypertrophic zone, in the
gefitinib-treated animals (the whole bone at low magnification [A, B] and
the growth plate region at high magnification [C, D]). PZ ¼ proliferative
zone; HZ ¼ hypertrophic zone. (E, F) Safranin O staining confirms the
increase in the length of the hypertrophic zone. (G) Quantification of
the lengths of the whole growth plate (GP) and each zone. n ¼ 5/group.
a
p < 0.001 versus vehicle. (H) Quantification of chondrocyte number
along the longitudinal length of cartilage.

group) and a similar length of BrdU-labeled area as vehicletreated rats (Fig. 3A), indicating that enlargement of the growth
plate is not due to an increased proliferative capacity of
chondrocytes.
We then examined chondrocyte differentiation by measuring
the mRNA expression of stage-specific differentiation markers in
the growth plate. Note that growth plate tissue was dissected
from tibias free of perichondrum and bone contamination, as
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Fig. 2. Gefitinib treatment expands the growth plate and decreases bone
volume in the primary spongiosa (PS) and secondary spongiosa (SS) of rat
long bones. (A) Magnified image of the COJ and primary spongiosa in
Goldner’s trichrome–stained rat tibias with or without gefitinib treatment.
Arrows indicate cartilage remnants (light blue) in the bone spicules. (B) mCT
images of longitudinal sections of distal femurs of vehicle- and gefitinibtreated rats. (C) Structural parameters of trabecular bone in the primary
spongiosa. (D) Structural parameters of trabecular bone in the secondary
spongiosa. BV/TV ¼ trabecular bone volume/tissue volume; TbTh ¼
trabecular thickness; TbSp ¼ trabecular separation; TbN ¼ trabecular
number. n ¼ 6/group. bp < 0.01; cp < 0.05 versus vehicle.

described under ‘‘Materials and Methods.’’ The genes for
aggrecan and type 2 collagen (Col2a1), Ihh, and type 10 collagen
(Col10a1) are specifically expressed in the proliferative, prehypertrophic, and hypertrophic zones, respectively. We found
ZHANG ET AL.

that while the expression levels of aggrecan, Col2a1, and Ihh were
not changed, Col10a1 increased about twofold in gefitinibtreated rats (Fig. 3B), which is consistent with the enlarged
hypertrophic zone in gefitinib-treated rats and in agreement
with the in situ data detecting Col10a1 mRNA expression in
the growth plate (Supplemental Fig. S2). Sox9 and Runx2 are
two master transcription factors that are essential for growth
plate development. Sox9 is expressed in proliferative
and prehypertrophic zones(22) and is important for determination of chondrocyte fate and maintenance of chondrocyte
proliferation,(23) whereas Runx2 is required for chondrocyte
maturation and terminal differentiation.(23) We found that
gefitinib-treated rats expressed similar levels of Sox9 and Runx2
mRNA in the growth plate as vehicle-treated animals (Fig. 3B).
Taken together, our data strongly suggest that chondrocyte
differentiation is not affected by EGFR inhibition.

Gefitinib-treated rats have normal angiogenesis
at the COJ
Previous reports have shown that suppressing the expression or
activity of VEGFa, an important regulator of angiogenesis during
endochondral ossification, inhibits blood vessel invasion into the
hypertrophic zone of long bone growth plates and results
in expansion of the hypertrophic zone.(24) To test whether
vascularization is impaired in our animal model, we used H&E
staining to identify red blood cells and their associated blood
vessels along the COJ. As shown in Fig. 3C, we did not observe
any overt difference in the number, location, orientation, or
morphology of blood vessels underneath the growth plate in
gefitinib-treated rats compared with vehicle-treated rats. This is
consistent with our immunohistochemistry results that endothelial cells do not express EGFR (Supplemental Fig. S4C) and
suggests that angiogenesis is not directly impaired by gefitinib.
qRT-PCR revealed that the mRNA expression of Vegfa, along with
another angiogenesis factor, transferrin,(25) was increased about
5.3- and 4.8-fold, respectively, in the growth plate after gefitinib
treatment (data not shown), which is consistent with expansion
of the hypertrophic zone.

Gefitinib treatment suppresses the ability of
chondrocytes to support osteoclastogenesis at the COJ
Osteoclasts at the COJ play an essential role in endochondral
ossification by secreting various proteinases to digest cartilage
ECM for vascular invasion and conversion from cartilage matrix
into bone matrix. Mice that are unable to generate osteoclasts
also develop enlarged hypertrophic zones in their growth
plates.(26) We therefore assessed the number of osteoclasts along
the COJ using TRAP staining. Notably, we observed a significant
decrease in the number of TRAPþ cells located just below the last
row of terminally differentiated chondrocytes in the gefitinib
group compared with the vehicle group (vehicle 10.9  1.0 cells/
mm versus gefitinib 5.5  0.7 cells/mm, p ¼ 0.01, n ¼ 6/group).
However, the number of TRAPþ cells in the area directly below
the COJ to 0.64 mm below the COJ was similar between these
two groups (vehicle 59.4  5.4 cells/mm2 versus gefitinib
58.0  5.6 cells/mm2, n ¼ 6 /group; Fig. 4A).
ROLE OF EGFR IN ENDOCHONDRAL OSSIFICATION

The aforementioned immunohistochemisty data (Supplemental Fig. S4D) and our previous report(21) demonstrate that
osteoclasts are not direct targets for gefitinib. To understand
how gefitinib treatment reduced the number of osteoclasts
along the COJ, we compared the mRNA levels of receptor
activator of nuclear factor kB ligand (RANKL), a major
determinant for osteoclastogenesis, and osteoprotegerin
(OPG), a decoy receptor for RANKL, in the growth plate using
qRT-PCR. Interestingly, we observed a 3.6-fold decrease in RANKL
expression but no significant change in OPG expression
( p ¼ 0.17) in the gefitinib group compared with control. These
changes result in an overall 60% decrease in the RANKL/OPG
ratio after gefitinib treatment (Fig. 4B). To determine whether
these changes were due to the direct action of gefitinib on
chondrocytes, we treated primary chondrocytes with TGF-a to
activate EGFR. qRT-PCR revealed that TGF-a upregulated RANKL
expression but suppressed OPG expression, resulting in 1.8-, 5.0-,
and 16.6-fold increases in the ratio of RANKL/OPG after 8, 24, and
48 hours of treatment, respectively (Fig. 4C). Moreover, this
regulation was completely abolished by inhibition of EGFR
activity (Fig. 4D). These data demonstrate that EGFR signaling
is important for chondrocytes to support osteoclastogenesis at
the COJ.

Inhibition of EGFR activity decreases matrix
metalloproteinase (MMP-9, -13, and -14) expression
and ECM degradation
MMPs are members of a family of zinc-dependent proteolytic
enzymes. Several of them are expressed at high levels in bone
and cartilage and essential for the cleavage of cartilage ECM and
remodeling of cartilage into bone. Blocking MMP activity either
by a broad-spectrum inhibitor(27) or by knocking down specific
MMP genes, such as Mmp9,(28) Mmp13,(29,30) and Mmp14,(31)
diminishes matrix degradation and expands the growth plate.
Interestingly, we found that the mRNA levels of these MMPs were
significantly suppressed three- to fourfold in the growth plate of
gefitinib-treated rats (Fig. 5A). Western blotting confirmed strong
decreases at the protein level (Fig. 5B). Moreover, gelatin
zymography showed that the activity of MMP-9 (gelatinase B), in
both pro and mature forms, was attenuated, whereas MMP-2
(gelatinase A) activity was not affected (Fig. 5C). In situ
hybridization further revealed that Mmp13 gene expression in
the terminally differentiated chondrocytes was suppressed
dramatically by gefitinib (Fig. 5D).
To test whether the decrease in MMP expression led to
accumulation of intact collagen fibers, polarized light microscopy was used to quantify the intensity of birefringent collagen in
the growth plate. In the vehicle group, we observed strong type 1
collagen birefringence in the primary spongiosa, most of which
was aligned with bone spicules. However, the birefringence in
the growth plate was weak and existed mostly in the longitudinal
septa between columns of chondrocytes (Fig. 5E). Quantitative
imaging analysis revealed that there was a significant 2.2-fold
increase in the intensity of birefringence in the growth plate
of gefitinib-treated rats. Moreover, picrosirius red staining for
collagen showed a similar increase in collagen birefringent
intensity in the gefitinib group (data not shown). Type 2 collagen
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Fig. 3. Gefitinib treatment does not alter chondrocyte proliferation, differentiation, and vascular invasion. (A) BrdU incorporation (brown staining) in the
proliferative zone of growth plates from vehicle- and gefitinib-treated rats. (B) qRT-PCR analysis of gene expression of stage-specific chondrocyte markers
(aggrecan, Col2a1, Ihh, and Col10a1) and transcription factors (Sox9 and Runx2). bp < 0.01 versus vehicle. (C) H&E staining of rat tibias shows that there is no
overt difference in localization, size, or morphology of blood vessels in the gefitinib-treated rats compared with the vehicle-treated rats. Red blood cells are
stained red with no blue nuclei.

is the major collagen in the growth plate. Immunohistochemical
staining showed an increase in type 2 collagen in the gefitinibtreated growth plate compared with control (Fig. 5F). This
increase is not due to an increase in gene expression because the
mRNA level of Col2a1 was not changed (Fig. 3B).

Accumulation of ECM proteins owing to decreases in MMP
levels should be accompanied by reduced ECM degradation.
Immunostaining for a neoepitope in the collagenase cleavage
site in the 3/4 fragment of type 2 collagen indicated that there
was decreased degraded type 2 collagen in the perilacunar

Fig. 4. Osteoclast differentiation at the COJ is delayed in gefitinib-treated rats. (A) TRAP staining (red) of rat tibias reveals that gefitinib-treated rats have
fewer osteoclasts at the COJ but comparable osteoclast number in the primary spongiosa underneath the junction. (B) qRT-PCR measurement of mRNA
expression of RANKL and OPG in the growth plate dissected from vehicle- and gefitinib-treated rats. (C) qRT-PCR measurement of mRNA expression
of RANKL and OPG in primary chondrocytes treated with TGF-a for indicated time points. The mRNA level of the control group at 1 hour was set to 1.
(D) qRT-PCR demonstrates that 5 mM gefitinib abolishes the effects of 24 hours of TGF-a treatment on RANKL and OPG expression in primary chondrocytes.
a
p < 0.001; bp < 0.01; cp < 0.05 versus control.
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Fig. 5. Blocking EGFR activity suppresses the expression of MMPs and ECM degradation in the growth plate. (A) qRT-PCR analyses of Mmp mRNA
expression in the growth plate tissues from vehicle- and gefitinib-treated rats. bp < 0.01; cp < 0.05 versus vehicle. (B) Western blotting shows that the
protein levels of MMP-9, -13, and -14 in the growth plates from gefitinib-treated rats were decreased to 7.9%  2.1%, 14.0%  12.6%, and 39.2%  10.5%,
respectively, of those from the vehicle-treated group, as measured by densitometric analysis. (C) Gelatin zymographic analysis of protein lysates from the
growth plate further confirms the decrease in MMP-9 activity in gefitinib-treated animals. The activity of MMP-2 was shown here as an internal control. The
amounts of pro (a) and mature (b) MMP-9 in the gefitinib-treated group decreased to 30% and 47% of that in vehicle-treated group, as measured by
densitometric analysis. (D) In situ hybridization reveals a decrease of MMP13 expression in the gefitinib-treated tibial growth plate. (E) Polarized light
microscopy of unstained tibial paraffin sections from vehicle- and gefitinib-treated rats. The sections were oriented with maximum birefringence
(white blue). The COJ is depicted as a dashed line separating the growth plate (GP) and the primary spongiosa (PS) areas. The intensity of birefringence
then was analyzed and quantified by ImageJ. n ¼ 6/group. bp < 0.01 versus vehicle. ( F) Immunostaining of type 2 collagen in the growth plate.
(G) Immunostaining of collagenase-produced 3/4 cleavage fragment of type 2 collagen. (H) Western blot of protein lysates from growth plate tissues using
an antibody to the MMP-cleaved aggrecan product.

surrounding of hypertrophic chondrocytes and at the COJ in
the gefitinib-treated group compared with the vehicle group
(Fig. 5G). As shown in Fig. 5H, Western blotting indicated that
the amount of MMP-cleaved aggrecan fragments also was
decreased in the gefitinib-treated growth plate. Taken together,
these data strongly suggest that ECM degradation is partially
blunted by EGFR inhibition.

EGFR signaling stimulates MMP expression in
primary chondrocytes
We next determined whether the decrease in MMP expression
was due to a direct effect of gefitinib on the EGFR in
chondrocytes. Primary chondrocytes were treated with TGF-a
to activate EGFR. qRT-PCR revealed that TGF-a increased Mmp9
mRNA 1.9-, 3.8-, and 12.8-fold at 8, 24, and 48 hours, respectively,
and increased Mmp13 mRNA 1.7-, 3.3-, and 23.9-fold at 8, 24, and
48 hours, respectively (Fig. 6A). However, Mmp14 mRNA was
increased only 1.6-fold at 48 hours. Western blot analyses
confirmed that the expression levels of MMP-9, -13, and -14 were
upregulated at the protein level. This stimulation was completely
ROLE OF EGFR IN ENDOCHONDRAL OSSIFICATION

abolished by gefitinib (Fig. 6B), indicating that TGF-a regulation
of MMPs is EGFR-dependent.

Mice deficient in chondrogenic EGFR activity have an
enlarged hypertropic zone
In the preceding experiments, oral administration of the EGFR
inhibitor to rats suppressed EGFR activity ubiquitously. To
exclude the possibility that gefitinib might act on cells other than
chondrocytes to affect growth plate development, we initially
generated Col2a1 promoter–driven Cre (Col2a1-Cre) Egfrflox/flox
mice. In neonatal mice, Col2a1-Cre was expressed in the
chondrocytes of the long bone epiphysis.(16) However, genotyping and Western blotting with these mice revealed an
incomplete deletion of Egfr alleles and no significant change
in the amount of EGFR protein in the epiphyseal cartilage
(Supplemental Fig. S5). To further reduce the remaining EGFR
activity, we introduced an EGFR dominant-negative allele,
Wa5,(15) and generated Col2a1-Cre EgfrWa5/f mice. Previously,
we have used this strategy successfully to characterize pre/
osteoblast-specific Egfr null mice.(20) Analyzing the long bone
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Fig. 6. EGFR signaling regulates MMP-9, -13, and -14 expression in primary chondrocytes. (A) Time course of TGF-a regulation of MMP expression. The
mRNA levels were analyzed by qRT-PCR and adjusted to the mRNA level in the control harvested at 1 hour. ap < 0.001; cp < 0.05 versus control. (B) Western
blots of MMP proteins in the primary chondrocytes after 4 days of TGF-a treatment. The medium was changed after 2 days, along with the addition of fresh
TGF-a. In the gefitinib lanes, 5 mM gefitinib was added to the cells 1 hour prior to TGF-a treatment. The blots were quantified by densitometric
measurement. The data were normalized against b-actin, and the corresponding values were shown underneath each blot.

growth plate at P5 revealed that while the Wa5 allele itself
(EgfrWa5/f mice) modestly increased the length of the hypertrophic zone (1.3-fold), introducing Col2-Cre further expanded
the hypertrophic zone dramatically to 2.0-fold compared with
Egfrþ/f mice (Fig. 7A, B). These data strongly demonstrate that
chondrogenic EGFR activity is essential for cartilage remodeling
into bone. Consistent with the gefitinib-treated rat results, we did
not observe any difference in the length of the proliferative zone
in these mice (Fig. 7B), implying that the major reason for the
expanded growth plate is also the delayed cartilage remodeling
into bone.

Discussion
Significant skeletal defects have long been noticed in mouse
models with abnormal EGFR activity. Recently, we reported that
EGFR ligands stimulate osteoclastogenesis indirectly by suppressing OPG expression and enhancing monocyte chemotactic
protein-1 (MCP1) expression in differentiating osteoblasts.(21)
Furthermore, we demonstrated that EGFR is an anabolic
regulator of bone formation that is important for the maintenance of a pool of mesenchymal stem cells and osteoprogenitors
in bone.(20) In this report, we demonstrated that EGFR signaling is
also an important regulator of postnatal growth plate development and endochondral ossification. Blocking EGFR activity
specifically with small-molecule inhibitors dramatically expanded the length of the growth plate, particularly the hypertrophic
zone, in rat long bones. While chondrocyte proliferation,
differentiation, and angiogenesis at the COJ were relatively
normal, the removal of hypertrophic cartilage matrix by
osteoclasts and MMPs was suppressed. Interestingly, the effect
of the EGFR inhibitor on the growth plate is reversible,
suggesting that normal cartilage matrix degradation is restored
rapidly after removal of EGFR inhibition. A similar growth plate
phenomenon is also observed after chondrocyte-specific
inactivation of the Egfr gene in mice and in Tgfa null mice
(Usmani and colleagues, submitted), further confirming that
EGFR signaling is critical for growth plate remodeling in long
bones.
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ECM degradation in the growth plate is an essential step in
endochondral ossification. The growth plate contains an ECM
mainly comprised of type 2 and type 10 collagens and the
aggregating proteoglycan (aggrecan). To form new bone,
hypertrophic chondrocytes and osteoclasts need to partially
degrade the growth plate ECM at the COJ, generating space for
osteoblasts to deposit bone matrix. MMPs, in particular MMP-9, 13, and -14, are key enzymes involved in this process. MMP-13,
also named collagenase 3, is the major protease that degrades
native type 2 collagen.(32) MMP-9 and -13 together are
responsible for MMP-dependent aggrecan cleavage.(30) MMP14, also named membrane type 1 MMP (MT1-MMP), functions as a
potent pericellular collagenase capable of degrading both type 1
and type 2 collagen(33) and is important for the formation of the
secondary ossification center.(31) Mice deficient in either MMP-9,
-13, or -14 all have an expanded hypertrophic zone in the growth
plate during early postnatal bone growth owing to impeded ECM
degradation, a phenotype similar to our EGFR inhibitor–treated
young rats. However, once Mmp9 knockout or Mmp13 knockout
mice reach adulthood, the enlarged growth plate is no longer
observed, likely owing to redundancy among the various
proteases.
MMP9, -13, and -14 are expressed by cells in and surrounding
the growth plate. MMP-13 is expressed mainly in hypertrophic
chondrocytes and osteoblasts.(34) In situ hybridization and
immunostaining indicate that cells with high MMP-9 expression
are osteoclasts(28,35) and TRAP cells of unknown lineage
beneath the hypertrophic cartilage.(26) Meanwhile, MMP-9
expression also was identified in the hypertrophic chondrocytes
of mouse cartilage by immunostaining(36) and throughout the
growth plate in 4-week-old rats by in situ hybridization.(37) MMP14 is expressed mainly in the resting and proliferative zones,
whereas the hypertrophic zone showed little expression.(38)
MMP-14 is also abundant in osteoclasts(39) and exhibits intense
staining in the region beneath the COJ.(38) To avoid possible
contamination of cells other than chondrocytes, we used a
stereomicroscope to dissect out the growth plate tissue from
rat tibias containing chondrocytes only but not osteoblasts,
osteoclasts, and other cells at the COJ and confirmed the
presence of only chondrocytes within our samples by histology.
ZHANG ET AL.

Fig. 7. Mice deficient in chondrogenic EGFR activity exhibit an enlarged
hypertrophic zone. (A) H&E staining of tibial growth plates from Col2-Cre
EgfrWa5/f mice and controls. Double-arrow lines indicate the hypertrophic
zone. (B) Quantification of the lengths of proliferative (PZ) and hypertrophic (HZ) zones. n ¼ 4 to 5/group. ap < 0.001 versus Egfrþ/f; bp < 0.005
versus EgfrWa5/f; cp < 0.05 versus Egfrþ/f. (C) A model of how EGFR
signaling stimulates cartilage degradation. Two mechanisms contribute
to this function of EGFR. First, EGFR signaling upregulates the expression
of MMP-9, -13, and -14 in the growth plate and thus is responsible
for cartilage ECM degradation. Second, EGFR signaling is important for
RANKL expression in the growth plate and thus is responsible for
osteoclastogenesis at the COJ.

We demonstrate that the growth plate samples do express
Mmp9, Mmp13, and Mmp14 mRNA and protein and that this
expression was attenuated by blocking EGFR activity. This is
consistent with a previous study that showed severe craniofacial
defects in Egfr null mice and diminished MMP secretion from
mandibular explants from these animals.(7) We show that the
decreases in the amounts of MMP are correlated with the
accumulation of collagen and decreases in degraded aggrecan
and type 2 collagen products in the growth plate. Further in vitro
experiments revealed that TGF-a stimulates MMP-9, -13, and -14
expression in primary chondrocytes via activation of EGFR. This
result suggests that gefitinib acts directly on chondrocytes in
vivo to block MMP expression. Taken together, these data
demonstrate that EGFR signaling is critical for maintaining
ROLE OF EGFR IN ENDOCHONDRAL OSSIFICATION

the expression of these three MMPs in the growth plate and
subsequently promoting ECM degradation.
In addition to the diminished expression of MMPs, our data
suggest that delayed osteoclast recruitment and differentiation
at the COJ could be another mechanism for expansion of the
growth plate after gefitinib treatment. We found that while the
number of osteoclasts in the primary spongiosa was unchanged,
the number of osteoclasts at the COJ was decreased significantly
in gefitinib-treated rats. A previous report showed that Egfr/
mice have delayed endochondral ossification and an enlarged
hypertrophic zone in the growth plate.(8) At E16.5, wild-type mice
had already formed primary ossification centers, whereas Egfr/
mice still had a continuous cartilage anlage in the middle of the
long bone. Wang and colleagues noticed that at that stage, the
number of osteoclasts adjacent to the hypertrophic cartilage in
Egfr/ mice was less than that in the bone marrow of wild-type
mice and concluded that the impaired endochondral ossification
in Egfr/ mice is due to the loss of EGFR signaling in osteoclasts.
However, their conclusion cannot explain their observation that
there was no difference in osteoclast number in the bone
marrow at later stage (E18.5) when the primary ossification
center was formed and the enlarged hypertrophic zone was still
prominent in the Egfr/ mice. It also cannot explain why we did
not observe any change in osteoclast number in the primary
spongiosa after gefitinib treatment. In addition, our previous
data showed that osteoclastic lineage cells do not express
functional EGFR,(21) and our current immunostaining showed
very weak EGFR staining in osteoclasts. Importantly, we also
show that chondrocyte-specific inactivation of EGFR (Col2a1-Cre
EgfrWa5/f mice) caused similar enlargement of the hypertrophic
zone postnatally. All these data strongly suggest that an
additional indirect mechanism may be responsible for mediating
the effects of EGFR on osteoclasts.
Here we attribute the decrease in osteoclast number to a
decrease in the RANKL/OPG ratio in the growth plate. RANKL and
OPG are expressed by hypertrophic chondrocytes in the growth
plate during embryonic development.(40) It is known that
vitamin D3 can regulate RANKL expression in chondrocytes
to promote osteoclast formation in vivo.(41) In vitro coculture
experiments demonstrate that chondrocytes are capable of
supporting osteoclastogenesis directly.(42) Since RANKL/OPG are
stimulated by TGF-a in primary chondrocytes, we conclude that
hypertrophic chondrocytes are the major determinant of
osteoclast formation at the COJ and that EGFR signaling in
chondrocytes is essential for this process. Notably, Tgfa null
mice also display reduced expression of RANKL and MMP13 in
cartilage (Usmani and colleagues, submitted).
In vitro chondrocyte culture experiments have demonstrated
that activation of EGFR signaling strongly stimulates chondrocyte proliferation,(43,44) inhibits chondrogenesis,(45) and suppresses the expression of chondrocyte matrix genes.(46)
Surprisingly, we found that gefitinib treatment did not alter
chondrocyte proliferation and differentiation in vivo. Since
immunostaining shows EGFR expression throughout the growth
plate, we reason that EGFR may be activated differentially within
these zones. A previous study of growth plate in chickens
suggested that EGF and TGF-a are expressed in the prehypertrophic and hypertrophic zones but not in the proliferative zone
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during early postnatal growth.(47) Expression of EGF-like ligands
only in mature chondrocytes can explain why inhibition of EGFR
activity affects RANKL and MMP expression in hypertrophic
chondrocytes but has no effect on chondrocyte proliferation
and differentiation. Further analysis to locate the activated EGFR
will be required to confirm this hypothesis.
In conclusion, our studies reveal a novel critical role of EGFR
in growth plate cartilage ECM remodeling. We demonstrate
that EGFR signaling regulates matrix degradation directly by
stimulating growth plate chondrocytes to express MMPs and
indirectly by supporting osteoclastogenesis at the COJ (Fig. 7C).
These two mechanisms may be complementarily interplayed.
It is possible that gefitinib-induced delay in growth plate
mineralization is secondary to the defects in matrix degradation
because MMP-9 and -13 are components of matrix vesicles(48)
that are responsible for cartilage calcification, and MMP-13
activity is important for chondrocyte mineralization in vitro.(49)
To date, no defects in human bone or cartilage growth have
been linked to alterations in the EGFR pathway. However, in
chickens, EGF may play a role in tibial dyschondroplasia, a
chicken growth plate disorder that bears resemblance to human
diseases such as osteochondrosis and metaphyseal chondroplasia. Chickens with this disorder show overexpression of EGF in
the proliferating zone and diminished expression of EGF and
TGF-a in the hypertrophic zone.(47) Future investigations are
needed to understand how EGFR regulates endochondral
ossification and whether alterations in this pathway lead to
human long bone growth defects.
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